View ValuationZIVO Bioscience 将来の成長Future 基準チェック /26ZIVO Bioscienceは、7.2%と112.2%でそれぞれ年率7.2%で利益と収益が成長すると予測される一方、EPSはgrowで41.3%年率。主要情報7.2%収益成長率41.26%EPS成長率Personal Products 収益成長8.5%収益成長率112.2%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日16 Nov 2023今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 07University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryZIVO Bioscience, Inc. announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Building upon the outcomes of the initial study, this second study aimed to assess and compare the performance of three different ZIVO formulations in both directly challenged and contact-exposed birds. The study affirmed earlier observations that ZIVO's active ingredients may positively influence LPAI transmission dynamics, while identifying the optimal formulation for further testing. In the first arm of the study, which involved birds receiving a direct challenge with LPAI, modest positive trends were observed in viral shedding reduction among ZIVO-treated groups compared with untreated controls. While these differences did not reach statistical significance, the findings suggest potential for ZIVO's formulations to lessen disease severity. Notably, the formulation consisting of a blend of four distinct algal-derived materials demonstrated a slower and less efficient spread of the virus. One bird treated with this combination showed no signs of infection post-exposure, indicating potential protective effects. These findings resulting from rigorous testing at the University of Delaware reinforce commitment to developing sustainable, non-antibiotic solutions for the poultry industry. The insights gained from this study show encouraging trends and identifying a superior formulation will be instrumental in guiding future research and product optimization efforts. Given the potential impact ZIVO's product can have on mitigating Avian influenza, a widespread issue in the nation's large poultry industry, the company submitted a funding request to the State of Michigan for $5.5 million to further research. Additionally, the company are applying for a portion of the previously announced $100 million Avian Influenza Poultry Innovation Grand Challenge from the USDA.お知らせ • Apr 28ZIVO Bioscience, Inc., Annual General Meeting, Jun 09, 2025ZIVO Bioscience, Inc., Annual General Meeting, Jun 09, 2025. Location: 2125 butterfield road, suite 100, mi 48084, troy, United Statesお知らせ • Dec 21ZIVO Bioscience, Inc. Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian InfluenzaZivo Bioscience, Inc. reported favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO's proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Key findings of statistical significance from the study include: A reduction in viral titers (viral shedding) in infected birds receiving ZIVO's products compared with untreated infected controls. A delay in transmission of LPAI when healthy birds were exposed to infected birds, suggesting a slower and less aggressive spread of disease. The two-part controlled study evaluated the efficacy of ZIVO's proprietary Active ingredients, previously shown to be efficacious for mitigating the effects of coccidiosis in broiler chickens, against LPAI. In the second part, healthy chickens were housed with infected birds, replicating a real-world, high-risk environment for disease transmission. Compared to an untreated control group, birds that received ZIVO's proprietary active ingredient that were housed with infected birds experienced a statistically significant delay in viral detection. This observed delay suggests that ZIVO's products limit viral replication within a host. These favorable results indicate that ZIVO's proprietary active Ingredients represent potential preventative measures for reducing the spread of LPAIV in commercial poultry operations and enhancing overall flock health. Multiple products were explored to identify the most effective strategies against LPAI. While some products were better at lowering the viral titer, others were more effective at slowing the spread, suggesting that an optimal product configuration could provide more comprehensive protection. The study's positive outcomes justify further research and product development, supporting the potential of ZIVO' pipeline to address both LPAIV infections as well as a broad spectrum of other viral challenges faced by the poultry industry. "The University of Delaware's findings provide compelling evidence that its feed ingredients could be valuable tools in mitigating the risk of avian influenza outbreaks without the limitations associated with vaccines. Reducing disease transmission can positively impact both animal welfare and the operations of producers. These study results represent a significant milestone in efforts to deliver science-driven, sustainable solutions to address serious challenges facing the global poultry industry".お知らせ • Aug 23ZIVO Bioscience, Inc. Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler ChickensZIVO Bioscience, Inc. reported favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens. The study, which was conducted in collaboration with a major global animal health company and replicated real-world poultry production environments, further validates the efficacy of ZIVO’s non-antibiotic, immune-modulating product designed for the treatment of coccidiosis. Funded by the major animal health company, the study focused on the overall health and productivity of birds challenged with the coccidiosis-causing parasite, Eimeria, while comparing administration of ZIVO’s product alone or in combination with either an ionophore-based treatment or a coccidiosis vaccine versus birds treated with the ionophore or vaccination alone. Uninfected/untreated healthy birds and infected/untreated birds served as negative and positive disease controls, respectively. In this study, broiler chickens infected with coccidiosis and treated with ZIVO’s product in combination with an anticoccidial ionophore or vaccination exhibited statistically significant improvements in both growth performance (as measured by feed conversion ratio, FCR) and clinical signs of disease (as measured by intestinal lesion scores), compared with chickens that received only the ionophore or vaccine. With respect to FCR over the 42-day grow-out period, groups treated with ZIVO’s product in combination with either the ionophore or vaccination performed on par with the healthy, uninfected control group.お知らせ • Apr 28ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024, at 10:00 US Eastern Standard Time. Location: 3600 Centerpoint Parkway Pontiac United States Agenda: To consider and approve the appointment of independent registered public accounting firm for the fiscal year ending December 31, 2024; to consider and approve the compensation of executive officers; and to consider and approve any other matters.お知らせ • Feb 16+ 1 more updateThe Nasdaq Stock Market to Delist the Common Stock of ZIVO BioscienceThe Nasdaq Stock Market announced on February 13, 2024, that it will delist the common stock and warrants of Zivo Bioscience, Inc. Zivo Bioscience's securities were suspended on November 27, 2023, and have not traded on Nasdaq since that time.お知らせ • Feb 08ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge StudyZivo Bioscience, Inc. announced additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. These new results, along with earlier findings, further demonstrate the benefits of ZIVO’s product across the broiler production value chain. ZIVO previously reported the effects of its product on the health of broiler chickens exposed to coccidiosis during the course of a 42-day grow out period, which is typical for the poultry industry. These health benefits included a statistically significant reduction in intestinal damage caused by the Eimeria parasite compared with untreated control birds. This improvement in intestinal health following parasite exposure was on par with the market-leading commercial ionophore. ZIVO now reports that this reduction in intestinal damage enables poultry farms to optimize feed utilization as measured by the Feed Conversion Ratio (FCR), which is the primary driver of profitability. Similar to the outcomes related to intestinal damage, ZIVO’s product resulted in a statistically significant improvement in FCR compared with untreated controls. Further, these results were not statistically different from the market-leading commercial ionophore.お知らせ • Jan 23Zivo Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler ChickensZivo Bioscience, Inc. announced positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. With these and earlier test results, ZIVO will pursue a partnership with a global animal health company for commercializing its coccidiosis product. The study design was similar to that of a previously successful 28-day challenge study but was extended through 42 days to replicate real-world conditions of the broiler production industry. The results of the study in which the ZIVO treatment groups and a placebo control were blinded to the independent study contractor confirm previously reported positive effects of ZIVO’s non-antibiotic alternative for maintaining broiler health against coccidiosis. Notably, the study also showed that the performance of ZIVO’s product candidate was comparable to that of a market leading anticoccidial product.お知らせ • Jan 18ZIVO Bioscience, Inc. announced that it has received $0.531142 million in fundingOn January 16, 2024, ZIVO Bioscience, Inc. closed the transaction.お知らせ • Nov 29Nasdaq Determines to Delist the ZIVO Bioscience's Common Stock from the Nasdaq Capital MarketOn November 22, 2023, the ZIVO Bioscience, Inc. was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist the Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective at the open of business, on November 27, 2023. Nasdaq further indicated that it will file a Form 25 Notification of Delisting with the Securities and Exchange Commission (the “SEC”). The Company has applied to have its common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OTC Markets Group Inc. for eligible securities traded over-the-counter. Pending approval, the Company expects that trading of the Company’s common stock will commence on the OTC Pink Sheets at the open of business on November 27, 2023. The transition to the quotation of the Company’s common stock on the OTC Markets will have no effect on the Company’s business or operations.業績と収益の成長予測MUN:9R80 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20252-7N/AN/A112/31/20242-7N/AN/A112/31/20230-8N/AN/A19/30/20230-9-7-7N/A6/30/20230-9-6-6N/A3/31/2023N/A-9-6-6N/A12/31/2022N/A-9-7-7N/A9/30/2022N/A-9-8-8N/A6/30/2022N/A-9-8-8N/A3/31/2022N/A-9-9-9N/A12/31/2021N/A-9-7-7N/A9/30/2021N/A-7-6-6N/A6/30/2021N/A-9-5-5N/A3/31/2021N/A-9-3-3N/A12/31/20200-9-3-3N/A9/30/20200-11-2-2N/A6/30/20200-10-3-3N/A3/31/20200-11-4-4N/A12/31/2019N/A-12-4-4N/A9/30/2019N/A-10-4-4N/A6/30/2019N/A-13-4-4N/A3/31/2019N/A-14-5-5N/A12/31/2018N/A-15-5-5N/A9/30/2018N/A-15-5-5N/A6/30/2018N/A-14-5-5N/A3/31/2018N/A-12-5-5N/A12/31/2017N/A-10-4-4N/A9/30/2017N/A-7-4-4N/A6/30/2017N/A-6N/A-3N/A3/31/2017N/A-7N/A-2N/A12/31/2016N/A-6N/A-3N/A9/30/2016N/A-6N/A-2N/A6/30/2016N/A-6N/A-2N/A3/31/2016N/A-6N/A-3N/A12/31/2015N/A-6N/A-2N/A9/30/2015N/A-4N/A-2N/A6/30/2015N/A-6N/A-3N/A3/31/2015N/A-5N/A-2N/A12/31/2014N/A1N/A-3N/A9/30/2014N/A0N/A-3N/A6/30/2014N/A-1N/A-3N/A3/31/2014N/A-5N/A-3N/A12/31/2013N/A-10N/A-3N/A9/30/2013N/A-11N/A-3N/A6/30/2013N/A-7N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 9R80今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 9R80今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: 9R80今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 9R80の収益 ( 112.2% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: 9R80の収益 ( 112.2% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 9R80の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/01/23 19:03終値2023/10/26 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ZIVO Bioscience, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Anthony VendettiMaxim Group
お知らせ • May 07University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryZIVO Bioscience, Inc. announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Building upon the outcomes of the initial study, this second study aimed to assess and compare the performance of three different ZIVO formulations in both directly challenged and contact-exposed birds. The study affirmed earlier observations that ZIVO's active ingredients may positively influence LPAI transmission dynamics, while identifying the optimal formulation for further testing. In the first arm of the study, which involved birds receiving a direct challenge with LPAI, modest positive trends were observed in viral shedding reduction among ZIVO-treated groups compared with untreated controls. While these differences did not reach statistical significance, the findings suggest potential for ZIVO's formulations to lessen disease severity. Notably, the formulation consisting of a blend of four distinct algal-derived materials demonstrated a slower and less efficient spread of the virus. One bird treated with this combination showed no signs of infection post-exposure, indicating potential protective effects. These findings resulting from rigorous testing at the University of Delaware reinforce commitment to developing sustainable, non-antibiotic solutions for the poultry industry. The insights gained from this study show encouraging trends and identifying a superior formulation will be instrumental in guiding future research and product optimization efforts. Given the potential impact ZIVO's product can have on mitigating Avian influenza, a widespread issue in the nation's large poultry industry, the company submitted a funding request to the State of Michigan for $5.5 million to further research. Additionally, the company are applying for a portion of the previously announced $100 million Avian Influenza Poultry Innovation Grand Challenge from the USDA.
お知らせ • Apr 28ZIVO Bioscience, Inc., Annual General Meeting, Jun 09, 2025ZIVO Bioscience, Inc., Annual General Meeting, Jun 09, 2025. Location: 2125 butterfield road, suite 100, mi 48084, troy, United States
お知らせ • Dec 21ZIVO Bioscience, Inc. Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian InfluenzaZivo Bioscience, Inc. reported favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO's proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Key findings of statistical significance from the study include: A reduction in viral titers (viral shedding) in infected birds receiving ZIVO's products compared with untreated infected controls. A delay in transmission of LPAI when healthy birds were exposed to infected birds, suggesting a slower and less aggressive spread of disease. The two-part controlled study evaluated the efficacy of ZIVO's proprietary Active ingredients, previously shown to be efficacious for mitigating the effects of coccidiosis in broiler chickens, against LPAI. In the second part, healthy chickens were housed with infected birds, replicating a real-world, high-risk environment for disease transmission. Compared to an untreated control group, birds that received ZIVO's proprietary active ingredient that were housed with infected birds experienced a statistically significant delay in viral detection. This observed delay suggests that ZIVO's products limit viral replication within a host. These favorable results indicate that ZIVO's proprietary active Ingredients represent potential preventative measures for reducing the spread of LPAIV in commercial poultry operations and enhancing overall flock health. Multiple products were explored to identify the most effective strategies against LPAI. While some products were better at lowering the viral titer, others were more effective at slowing the spread, suggesting that an optimal product configuration could provide more comprehensive protection. The study's positive outcomes justify further research and product development, supporting the potential of ZIVO' pipeline to address both LPAIV infections as well as a broad spectrum of other viral challenges faced by the poultry industry. "The University of Delaware's findings provide compelling evidence that its feed ingredients could be valuable tools in mitigating the risk of avian influenza outbreaks without the limitations associated with vaccines. Reducing disease transmission can positively impact both animal welfare and the operations of producers. These study results represent a significant milestone in efforts to deliver science-driven, sustainable solutions to address serious challenges facing the global poultry industry".
お知らせ • Aug 23ZIVO Bioscience, Inc. Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler ChickensZIVO Bioscience, Inc. reported favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens. The study, which was conducted in collaboration with a major global animal health company and replicated real-world poultry production environments, further validates the efficacy of ZIVO’s non-antibiotic, immune-modulating product designed for the treatment of coccidiosis. Funded by the major animal health company, the study focused on the overall health and productivity of birds challenged with the coccidiosis-causing parasite, Eimeria, while comparing administration of ZIVO’s product alone or in combination with either an ionophore-based treatment or a coccidiosis vaccine versus birds treated with the ionophore or vaccination alone. Uninfected/untreated healthy birds and infected/untreated birds served as negative and positive disease controls, respectively. In this study, broiler chickens infected with coccidiosis and treated with ZIVO’s product in combination with an anticoccidial ionophore or vaccination exhibited statistically significant improvements in both growth performance (as measured by feed conversion ratio, FCR) and clinical signs of disease (as measured by intestinal lesion scores), compared with chickens that received only the ionophore or vaccine. With respect to FCR over the 42-day grow-out period, groups treated with ZIVO’s product in combination with either the ionophore or vaccination performed on par with the healthy, uninfected control group.
お知らせ • Apr 28ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024, at 10:00 US Eastern Standard Time. Location: 3600 Centerpoint Parkway Pontiac United States Agenda: To consider and approve the appointment of independent registered public accounting firm for the fiscal year ending December 31, 2024; to consider and approve the compensation of executive officers; and to consider and approve any other matters.
お知らせ • Feb 16+ 1 more updateThe Nasdaq Stock Market to Delist the Common Stock of ZIVO BioscienceThe Nasdaq Stock Market announced on February 13, 2024, that it will delist the common stock and warrants of Zivo Bioscience, Inc. Zivo Bioscience's securities were suspended on November 27, 2023, and have not traded on Nasdaq since that time.
お知らせ • Feb 08ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge StudyZivo Bioscience, Inc. announced additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. These new results, along with earlier findings, further demonstrate the benefits of ZIVO’s product across the broiler production value chain. ZIVO previously reported the effects of its product on the health of broiler chickens exposed to coccidiosis during the course of a 42-day grow out period, which is typical for the poultry industry. These health benefits included a statistically significant reduction in intestinal damage caused by the Eimeria parasite compared with untreated control birds. This improvement in intestinal health following parasite exposure was on par with the market-leading commercial ionophore. ZIVO now reports that this reduction in intestinal damage enables poultry farms to optimize feed utilization as measured by the Feed Conversion Ratio (FCR), which is the primary driver of profitability. Similar to the outcomes related to intestinal damage, ZIVO’s product resulted in a statistically significant improvement in FCR compared with untreated controls. Further, these results were not statistically different from the market-leading commercial ionophore.
お知らせ • Jan 23Zivo Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler ChickensZivo Bioscience, Inc. announced positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. With these and earlier test results, ZIVO will pursue a partnership with a global animal health company for commercializing its coccidiosis product. The study design was similar to that of a previously successful 28-day challenge study but was extended through 42 days to replicate real-world conditions of the broiler production industry. The results of the study in which the ZIVO treatment groups and a placebo control were blinded to the independent study contractor confirm previously reported positive effects of ZIVO’s non-antibiotic alternative for maintaining broiler health against coccidiosis. Notably, the study also showed that the performance of ZIVO’s product candidate was comparable to that of a market leading anticoccidial product.
お知らせ • Jan 18ZIVO Bioscience, Inc. announced that it has received $0.531142 million in fundingOn January 16, 2024, ZIVO Bioscience, Inc. closed the transaction.
お知らせ • Nov 29Nasdaq Determines to Delist the ZIVO Bioscience's Common Stock from the Nasdaq Capital MarketOn November 22, 2023, the ZIVO Bioscience, Inc. was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist the Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective at the open of business, on November 27, 2023. Nasdaq further indicated that it will file a Form 25 Notification of Delisting with the Securities and Exchange Commission (the “SEC”). The Company has applied to have its common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OTC Markets Group Inc. for eligible securities traded over-the-counter. Pending approval, the Company expects that trading of the Company’s common stock will commence on the OTC Pink Sheets at the open of business on November 27, 2023. The transition to the quotation of the Company’s common stock on the OTC Markets will have no effect on the Company’s business or operations.